COVID-19, microangiopathy, hemostatic activation, and complement
Open Access
- 22 June 2020
- journal article
- editorial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 130 (8), 3950-3953
- https://doi.org/10.1172/jci140183
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutationBlood, 2017
- Complement, a target for therapy in inflammatory and degenerative diseasesNature Reviews Drug Discovery, 2015
- Paroxysmal nocturnal hemoglobinuriaBlood, 2014
- Platelet-leukocyte interactions in thrombosisThrombosis Research, 2012
- Genetics and complement in atypical HUSPediatric Nephrology, 2010
- Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia–reperfusion injuryExpert Opinion on Biological Therapy, 2007
- Regulation of Toll-like receptor–mediated inflammatory response by complement in vivoBlood, 2007
- A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation PathwaysThe Journal of Immunology, 2006
- Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation.1995
- Role of heparan sulfate in immune system-blood vessel interactionsImmunology Today, 1993